Table VII.
Joint effect survival analysis between ALDH1L1 and TP53 mRNA expression level in GSE14520 HBV-related HCC patients.
| Group | ALDH1L1 expression | TP53 expression | Patients (n=218) | No. of events (%) | MST (months) | Adjusted HR (95% CI) | Adjusted P-valuea |
|---|---|---|---|---|---|---|---|
| DFS | |||||||
| i | Low | Low | 38 | 25 (65.8) | 23 | 1 | |
| ii | Low | High | 71 | 41 (57.7) | 35 | 0.675 (0.406–1.122) | 0.129 |
| iii | High | Low | 71 | 33 (46.5) | 57 | 0.460 (0.266–0.795) | 0.005 |
| iiii | High | High | 38 | 22 (57.9) | 36 | 0.614 (0.342–1.101) | 0.102 |
| OS | |||||||
| a | Low | Low | 38 | 22 (57.9) | 30 | 1 | |
| b | Low | High | 71 | 32 (45.1) | NA | 0.524 (0.300–0.914) | 0.023 |
| c | High | Low | 71 | 15 (21.1) | NA | 0.211 (0.105–0.422) | 0.000011 |
| d | High | High | 38 | 15 (39.5) | NA | 0.434 (0.222–0.846) | 0.014 |
a
Adjustment for age, sex, cirrhosis, BCLC stage, serum AFP level. ALDH1L1, aldehyde dehydrogenase 1 family member L1; HBV, hepatitis B virus; HCC, hepatocellular carcinoma; TP53, tumor protein p53; DFS, disease-free survival; OS, overall survival; MST, median survival time; HR, hazard ratio; CI, confidence interval.